New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx and more

At Reuters Pharma USA in Philadelphia, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.

In this video recorded at the event, Hilberdink discusses a wide range of topics including Boehringer’s pipeline, which includes the first significant improvement in pulmonary fibrosis in a decade, and why it’s far from too late to get into the GLP-1 game, especially with a product that could address new opportunities in MASH.

Hilberdink talks about how his experience at Novo Nordisk prepared him for continued work in the obesity space, as well as for helming the US side of a European global pharma.

They also get into digital therapeutics and why Boehringer Ingelheim is developing one in the mental health space, despite some recent rockiness in the DTx space.

Finally, Hilberdink tells us about the culture at Boehringer Ingelheim and why the private company’s independence makes it special. You can check out the article here to learn more about what Hilberdink had to say on stage at Reuters.